J&J racks up another diabetes no from Germany's IQWiG
This article was originally published in Scrip
Executive Summary
Germany's health technology appraisal institute, IQWiG, has said that Johnson & Johnson's fixed-dose combination of canagliflozin and metformin, marketed as Invokamet, has no proven added benefit over comparators. IQWiG is notoriously hard on novel diabetes products, and this is not the first time it has rejected a canagliflozin-based product.